Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 12

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Facioscapulohumeral muscular dystrophy

Recruiting

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Phenylketonuria

Recruiting

A Study of Repinatrabit Compared to Placebo for Treatment of Patients with Phenylketonuria

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Neurodevelopmental disorder

Recruiting

A Study of Gene Replacement Therapy for Children with CTNNB1 Syndrome Using Adeno-Associated Viral Vector Serotype 9 Containing the Human CTNNB1 Gene

InvestigationalNo placebo
Countries:SloveniaSlovenia
  • Participants:0–17 years
  • Substances:ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE
  • Sponsor:Fundacija CTNNB1 Ustanova Za Raziskave Na Podrocju Genske Terapije

Migraine

Recruiting

A Study Testing Cabergoline to Prevent and Treat Episodic Migraine in Patients with Recurring Migraine Headaches

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cabergoline
  • Sponsor:Region Midtjylland

Dementia with Lewy bodies

Recruiting

A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acp-204 Tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Ischaemic stroke

Recruiting

A Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride Solution 0.9%
  • Sponsor:TargED Biopharmaceuticals B.V.

Dementia with Lewy bodies

Recruiting

A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acp-204 Tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Central nervous system lymphoma

Recruiting

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia of the Alzheimer's type with delusions

Recruiting

A Study of Fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
  • Sponsor:Maplight Therapeutics Inc.

Multiple sclerosis

Recruiting

Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:ACICLOVIR SODIUM
  • Sponsor:Region Uppsala

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:IMEROPRUBART
  • Sponsor:Immunovant Sciences GmbH

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.